tiprankstipranks
Trending News
More News >
Shandong Weigao Group Medical Polymer Co Ltd Class H (HK:1066)
:1066

Shandong Weigao Group Medical Polymer Co (1066) AI Stock Analysis

Compare
1 Followers

Top Page

HK

Shandong Weigao Group Medical Polymer Co

(OTC:1066)

Rating:74Outperform
Price Target:
Shandong Weigao Group Medical Polymer Co has a solid financial foundation with strong profitability and stable financial position, though it faces challenges in revenue growth and cash flow management. The stock's technical indicators suggest positive momentum, and its valuation is attractive, offering a reasonable P/E ratio and a solid dividend yield. These factors contribute to a moderately strong overall stock score.

Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)

Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model

Company DescriptionShandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.
How the Company Makes MoneyShandong Weigao Group Medical Polymer Co. makes money through the manufacture and sale of a diverse portfolio of medical products. Its key revenue streams include single-use medical devices such as syringes, infusion sets, and blood bags. Additionally, the company generates income from its orthopedic materials and blood purification equipment segments. The company benefits from strategic partnerships and collaborations with healthcare institutions, which help to expand its market reach and product offerings. Revenue is also driven by its strong distribution network and its ability to innovate and meet the growing demand for medical products both domestically and internationally.

Shandong Weigao Group Medical Polymer Co Financial Statement Overview

Summary
Shandong Weigao Group Medical Polymer Co demonstrates strong profitability and a stable financial position, with healthy margins and conservative leverage. However, the slight decline in revenue and the lack of detailed cash flow data for the latest year suggest areas for improvement, particularly in cash flow management and revenue growth.
Income Statement
75
Positive
The company shows strong profitability with a consistent gross profit margin around 50% and a stable net profit margin in the range of 15-20%. However, there has been a slight decline in revenue growth, with a negative growth rate of approximately -1.1% from the previous year. EBIT and EBITDA margins remain healthy, indicating efficient cost management.
Balance Sheet
80
Positive
The balance sheet reflects a stable financial position. The debt-to-equity ratio is low, suggesting prudent leverage, while the equity ratio indicates a strong equity base with around 68% of total assets financed by equity. Return on Equity (ROE) has been relatively stable, reflecting decent returns to shareholders.
Cash Flow
65
Positive
The company has shown positive free cash flow, though the free cash flow growth rate is unavailable for the latest year. The operating cash flow to net income ratio is not calculable due to missing operating cash flow data for the latest year, indicating potential cash flow management issues that need addressing.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
13.09B13.23B13.62B13.15B11.35B
Gross Profit
6.58B6.64B7.11B7.27B6.46B
EBIT
2.39B2.18B3.56B3.32B2.61B
EBITDA
3.14B3.55B4.38B3.75B3.30B
Net Income Common Stockholders
2.07B2.00B2.76B2.28B2.09B
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.32B7.33B7.36B7.06B5.98B
Total Assets
34.76B33.67B33.20B30.37B27.34B
Total Debt
4.19B4.17B4.49B4.14B4.32B
Net Debt
-3.59B-2.82B-2.37B-2.49B-1.19B
Total Liabilities
9.42B9.68B9.75B9.46B8.95B
Stockholders Equity
23.75B22.45B21.67B19.27B17.55B
Cash FlowFree Cash Flow
2.14B2.11B1.10B1.92B1.70B
Operating Cash Flow
2.79B2.80B2.21B3.04B2.70B
Investing Cash Flow
-1.10B-1.39B-2.57B-1.48B423.22M
Financing Cash Flow
-1.60B-2.16B-1.02B-538.08M-1.79B

Shandong Weigao Group Medical Polymer Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.91
Price Trends
50DMA
5.62
Positive
100DMA
5.19
Positive
200DMA
4.87
Positive
Market Momentum
MACD
0.04
Negative
RSI
60.93
Neutral
STOCH
85.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Positive. The current price of 5.91 is above the 20-day moving average (MA) of 5.67, above the 50-day MA of 5.62, and above the 200-day MA of 4.87, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.93 is Neutral, neither overbought nor oversold. The STOCH value of 85.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1066.

Shandong Weigao Group Medical Polymer Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$25.87B11.598.95%3.60%-3.09%0.67%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
DE50J
€968.83M12.4418.36%3.92%
DEPWE
€177.74M10.563.72%8.47%
DE1MD
€434.51M8.8115.04%4.47%
68
Neutral
HK$16.05B30.0328.81%1.05%14.99%31.70%
66
Neutral
HK$4.52B20.3211.24%1.17%11.23%20.39%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1066
Shandong Weigao Group Medical Polymer Co
5.91
1.69
39.95%
DE:50J
Kangji Medical Holdings Limited
0.79
0.14
21.54%
DE:PWE
PW Medtech Group Ltd.
0.13
0.02
18.18%
DE:1MD
Modern Dental Group Limited
0.45
-0.04
-8.16%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
25.00
-2.45
-8.93%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
34.85
23.78
214.81%

Shandong Weigao Group Medical Polymer Co Corporate Events

Shandong Weigao Group Announces Leadership Change
May 28, 2025

Shandong Weigao Group Medical Polymer Company Limited announced a change in its board leadership effective 28 May 2025. Mr. Tang Zhengpeng has resigned as Vice-Chairman but will continue his role as a non-executive Director and committee member. Ms. Yan Xia, previously a non-executive Director, will succeed him as Vice-Chairman. This leadership transition is part of the company’s strategic reassignment of duties and responsibilities, potentially impacting its governance and stakeholder relations.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Announces Board Composition
May 28, 2025

Shandong Weigao Group Medical Polymer Company Limited has announced the composition of its board of directors and their respective roles. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and operational oversight, which is crucial for stakeholders and investors.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Announces Final Dividend for 2024
May 27, 2025

Shandong Weigao Group Medical Polymer Co. has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024, with shareholder approval scheduled for May 27, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.0888, with a payment date set for July 11, 2025. The announcement also details the withholding tax rates applicable to non-resident shareholders, with a 10% rate for enterprises and individuals outside China and a 20% rate for domestic individual investors using the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Announces Successful AGM and Dividend Payment
May 27, 2025

Shandong Weigao Group Medical Polymer Company Limited held its Annual General Meeting on 27 May 2025, where all proposed resolutions were successfully passed by poll. Key resolutions included the approval of the audited financial statements for 2024, the declaration of a final dividend, and the reappointment of Deloitte Touche Tohmatsu as the company’s auditor. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued stability and growth.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Makes Regulatory Announcement
Apr 30, 2025

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, which was also published on the Shanghai Stock Exchange’s website, highlights the company’s adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence positively.

Shandong Weigao Announces AGM with Key Resolutions
Apr 29, 2025

Shandong Weigao Group Medical Polymer Company Limited has announced its upcoming annual general meeting (AGM) scheduled for May 27, 2025. The AGM will address various resolutions, including the approval of the company’s audited financial statements for 2024, the declaration of a final dividend, re-appointment of auditors, and re-election of directors and supervisors. Additionally, a special resolution will consider granting the board a general mandate to issue and deal with shares. These resolutions are crucial for the company’s governance and strategic planning, potentially impacting its market positioning and shareholder value.

Shandong Weigao Group Announces Regulatory Compliance Update
Mar 26, 2025

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, signifies the company’s adherence to regulatory standards and may impact its market positioning by enhancing transparency and investor confidence.

Shandong Weigao Group Announces Overseas Regulatory Update
Mar 26, 2025

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, is part of the company’s ongoing regulatory obligations, reflecting its commitment to transparency and adherence to market regulations.

Shandong Weigao Group Makes Overseas Regulatory Announcement
Mar 26, 2025

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement was also published on the Shanghai Stock Exchange’s website, indicating the company’s adherence to regulatory standards and its commitment to transparency in its operations.

Shandong Weigao Group Announces Final Dividend for 2024
Mar 26, 2025

Shandong Weigao Group Medical Polymer Co has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024. This announcement reflects the company’s financial health and commitment to returning value to its shareholders, potentially impacting its market positioning positively.

Shandong Weigao Group Reports Increased Profit Amid Revenue Dip
Mar 26, 2025

Shandong Weigao Group Medical Polymer Company Limited reported a slight decrease in revenue for the year ended December 31, 2024, with a total of approximately RMB13.09 billion, down 1.1% from the previous year. However, the company achieved a 3.2% increase in net profit attributable to its owners, reaching approximately RMB2.07 billion. The directors have recommended a final dividend of RMB0.1235 per share, pending shareholder approval. This financial performance highlights the company’s resilience and potential for growth despite a challenging market environment.

Shandong Weigao Group Schedules Board Meeting for Annual Results and Dividend Decision
Mar 11, 2025

Shandong Weigao Group Medical Polymer Co. announced that its board of directors will meet on March 26, 2025, to review and approve the audited annual results for the year ending December 31, 2024. The meeting will also consider the potential declaration of a final dividend, which could impact shareholder returns and reflect the company’s financial health.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.